Allon Therapeutics Completes $10 Million Financing Agreement with Isar Pharma

Isar Pharma K/S, a wholly owned limited partnership of Nordic Biotech Venture Fund II K/S, has given Allon Therapeutics $10 million to advance clinical development of davunetide, its lead neuroprotective compound with potential to treat ALS and other neurological diseases. The new funds will ensure that a pivotal clinical trial of davunetide in progressive supranuclear palsy patients.

Click here to read more.

Share this: